venBio Partners — 2015 Investments
5 investments dated 2015 · listed companies and verified rows first · show all
Precision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)Jeff Smith(Co-founder)Derek Jantz(Co-founder)TODD MELBY(Executive Officer)
Board seatRobert Adelman· per SEC Form D
Co-investorsage1Aliment CapitalBrace PharmaF-Prime CapitalOCV PartnersOUP (Osage University Partners)+4 more
BiotechDublin 2
Jason Lettman(Director)
Board seatJaume PonsCorey Goodman· per SEC Form D · $36M raise · filed May 2015
NASDAQ-listed company developing therapies for complement cascade-driven diseases in haematology, ophthalmology, and nephrology.
Crestwood, US
Board seatRobert Adelman· per SEC Form D
Co-investorsEMBL VenturesEpidarex Capital
San Diego clinical-stage biopharma developing non-bile acid FXR agonists for liver and gastrointestinal diseases.
BiotechSan Diego, US
Ronald Evans(Director)Trisha Millican(Executive Officer)Ken Song(Executive Officer, Director)
BoardKristina Burow(Director)inRichard Heyman(Director)inAmir Nashat(Director)in
Board seatRobert Adelman· per SEC Form D · $37.8M raise · filed Nov 2016
Co-investorsage1EcoR1 CapitalLAVLilly Asia VenturesNew Enterprise Associates (NEA)Vivo Capital+2 more
BiotechSan Francisco, US
Curt Bradshaw(Executive Officer, Director, Promoter)Frank Muhlenbeck(Mr. Muhlenbeck is a Manager of the Issuer.)Louis Tartaglia(Mr. Tartaglia is a Manager of the Issuer.)
BoardCorey Goodman(Executive Officer, Director, Promoter)inSteven Dowdy(Director)
Board seatRobert Adelman· per SEC Form D · $4M raise · filed Dec 2015
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.